Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | HPGDS | O60760 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12828717 | 0.92 | SMN1; SMN2 (0.54) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL1472978 | 0.90 | SMN1; SMN2 (0.47) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL1472807 | 0.86 | SMN1; SMN2 (0.43) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL12828488 | 0.84 | KDM4E (0.45) | SMN1; SMN2THRBGAAKDM4EPKM | |
| SCHEMBL1473057 | 0.84 | KDM4E (0.45) | SMN1; SMN2THRBGAAKDM4EPKM | |
| SCHEMBL1474748 | 0.83 | KDM4E (0.44) | SMN1; SMN2THRBGAAKDM4EPKM | |
| SCHEMBL1473072 | 0.82 | KDM4E (0.43) | SMN1; SMN2THRBGAAKDM4EPKM | |
| SCHEMBL1473500 | 0.82 | GPR119 (0.46) | SMN1; SMN2THRBGAAKDM4EPKM | |
| SCHEMBL12828724 | 0.81 | HDAC4 (0.46) | SMN1; SMN2THRBGAAMAPTKDM4E | |
| SCHEMBL12829040 | 0.81 | KDM4E (0.43) | SMN1; SMN2THRBGAAKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915283-B2 | e.g. 1-[4-(1-Phenyl-1-(pyrazinyl)-methylene)-piperidin-1-yl]-2-(4-methoxy-7-pyrazinyl-6-azaindol-3-yl)-ethane-1,2-dione; viricides for prophylaxis of lympadenopathy associated virus; synergystic mixtures with immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080188481-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-07 | — | — | US | disclosed |
| US-7348337-B2 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188481-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | IDO1, IDO2, INMT | SMN1; SMN2 4771/4885THRB 4113/4885GAA 1735/4885 |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | IDO1, IDO2, INMT | SMN1; SMN2 4654/4885THRB 4187/4885GAA 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.